Consensus Valerio Therapeutics Börse Stuttgart

Equities

C4X

FR0010095596

Market Closed - Börse Stuttgart Other stock markets 09:41:51 2024-05-31 EDT			5-day change	1st Jan Change
0.0974 ^EUR	-1.02%		+2.53%	-35.92%

05-22	Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial	CI
04-30	Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Valerio Therapeutics

Price target over the last 5 years

History of analyst recommendation changes

2437a70f5d494ab0.T6nijUVSEflfO76noL0Dd77crH0zDNIZJaoAY9Y8NSU.Ld696D0FJ5IIdvLWkeJSJsqN_gx2SrVOaOU2EKdOYWMFy630CH9hiRRx6w~3dfd486351e66fa3679f6b5e8b5a9200

Analyst Recommendations on Valerio Therapeutics

Onxeo : Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation	20-05-29	PU
Bryan Garnier & Co Initiates Coverage of Onxeo with a “Buy” Recommendation	20-05-27	GL
Onxeo : Bryan Garnier & Co Initiates the Coverage of Onxeo with a “Buy” Recommendation	20-05-27	BU

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.108 EUR

Average target price

1.2 EUR

Spread / Average Target

+1,011.11%

High Price Target

1.2 EUR

Spread / Highest target

+1,011.11%

Low Price Target

1.2 EUR

Spread / Lowest Target

+1,011.11%

Consensus detail

Consensus revision (last 18 months)

Annual profits - Rate of surprise

Company calendar